David Page is an Oncology physician affiliated with Providence Portland Medical Center. OpenAlex indexes 157 publications with 6,574 citations (h-index 29); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4805 NE Glisan St Ste 11n
Portland, OR 972132933
Telephone
503-215-1350Provider last certified this registry record 22 Mar 2021.
Clinical trials
- CAN1012 in Pre-Malignant DCIS and LCIS
Sponsor: Providence Health & Services
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Sponsor: Providence Health & Services
- Spinal Cord Stimulation Trial to Permanent Prediction
Sponsor: Abbott Medical Devices
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202519 payments$11,727openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202510 payments
- Stemline Therapeutics Inc.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
87.1%Aromatase Inhibitor62.2%Anastrozole52%Letrozole32%Exemestane16%Part D≥64 patientsKinase inhibitor14.7%Ibrance45%Kisqali33%Verzenio21%Part D<11 patients+ 2 more classes in this area
Nervous system
12.9%Gabapentinoids5.1%Gabapentin100%Part D<11 patientsOpioid Agonist3.3%Oxycodone Hcl100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Noninvasive Ventilation for Preoxygenation during Emergency Intubation
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Heffner, MD
Providence Portland Medical Center
Alison Conlin, MD
Providence Portland Medical Center
Rom Leidner, MD
Providence Portland Medical Center
Herschel Wallen, MD
Providence Portland Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”